Biomarin has just published a relase describing, in brief, the results of the phase 1 clinical trial with BMN-111, the first potential pharmacological treatment for achondroplasia.
In summary, Biomarin informs that there were no major side effect related to the doses used in the volunteers. Transient hypotension was identified, as expected, and is probably associated with CNP natural actions.
Biomarin, in face of the results of these tests, decided to progress BMN-111 to phase 2.
For more information, follow this Biomarin link:
For more information about CNP in achondorplasia you can read this article previously published in the blog: